青蒿琥酯作为佐剂增强狂犬病疫苗的免疫应答
该研究在小鼠中探讨青蒿素衍生物青蒿琥酯和双氢青蒿素能否增强灭活狂犬病病毒的免疫原性。以5 mg/kg剂量肌内注射青蒿琥酯或双氢青蒿素未引起小鼠体重下降和异常症状。与磷酸盐缓冲液(PBS)对照组相比,青蒿琥酯共处理组狂犬病病毒中和抗体(VNA)滴度显著更高,且能抵抗致死性狂犬病病毒攻击而存活;双氢青蒿素共处理未提高攻击后小鼠的存活率。结果表明青蒿琥酯可作为狂犬病疫苗接种的新候选佐剂。
要点
- 青蒿琥酯共处理组狂犬病病毒中和抗体滴度显著高于PBS对照组。
- 青蒿琥酯共处理小鼠在致死性狂犬病病毒攻击后存活,PBS对照组未存活。
- 双氢青蒿素共处理未提高攻击后小鼠的存活率。
核心结论
- 青蒿琥酯可作为狂犬病疫苗接种的新候选佐剂。
研究设计与样本
- 研究在小鼠中探讨青蒿素衍生物青蒿琥酯和双氢青蒿素能否增强灭活狂犬病病毒的免疫原性。
- 以5 mg/kg剂量肌内注射青蒿琥酯或双氢青蒿素,未引起小鼠体重下降和异常症状。
- 小鼠用灭活CVS-11或灭活rHEP-dG联合青蒿琥酯或双氢青蒿素经肌内注射免疫,采血检测病毒中和抗体(VNA)滴度,随后进行攻击实验。
主要发现
- 青蒿琥酯共处理组狂犬病VNA滴度显著高于PBS对照组,双氢青蒿素共处理组未显著高于PBS对照组。
- 青蒿琥酯共处理小鼠在致死性狂犬病病毒攻击后存活,PBS对照组未存活。
- 双氢青蒿素共处理未提高攻击后小鼠的存活率。
关键数值与推荐
- 青蒿琥酯或双氢青蒿素肌内注射剂量为5 mg/kg。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rabies is an ancient zoonosis that continues to be an important health problem worldwide. Vaccination with rabies vaccine is the most important strategy to prevent rabies. Adjuvants contribute to the immune response of viral vaccine. The aim of this study was to investigate whether artemisinin derivatives artesunate and dihydroartemisinin could enhance the immunogenicity of inactivated rabies virus in mice. Administration of artesunate or dihydroartemisinin by intramuscular injection at a dose of 5 mg/kg did not cause body weight loss and unusual symptoms in mice. Mice were immunized with inactivated CVS-11 or inactivated rHEP-dG together with either artesunate or dihydroartemisinin through intramuscular injection. Blood samples were collected to investigate the virus-neutralizing antibody (VNA) titers, and challenge assays were then conducted. The results showed that the rabies VNA titers in mice co-treated with artesunate rather than dihydroartemisinin were significantly higher than in the control animals treated with the phosphate buffered saline (PBS). In addition, mice co-treated with artesunate survived from lethal rabies virus challenge compared with those treated with PBS. In contrast, co-treatment with dihydroartemisinin did not improve the survival rate of the challenged mice. The findings indicate that artesunate could be used as a new candidate adjuvant for rabies vaccination.
引用
- Luo J, Zhang Y, He H, et al. Artesunate enhances the immune response of rabies vaccine as an adjuvant. Vaccine. 2019. PMID: 31582270. doi:10.1016/j.vaccine.2019.09.077
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。